Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

被引:230
|
作者
McNutt, Markey C.
Lagace, Thomas A.
Horton, Jay D. [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1074/jbc.C700095200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed similar to 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.
引用
收藏
页码:20799 / 20803
页数:5
相关论文
共 50 条
  • [1] Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
    McNutt, Markey C.
    Kwon, Hyock Joo
    Chen, Chiyuan
    Chen, Justin R.
    Horton, Jay D.
    Lagace, Thomas A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (16) : 10561 - 10570
  • [2] Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells
    Lammi, Carmen
    Zanoni, Chiara
    Aiello, Gilda
    Arnoldi, Anna
    Grazioso, Giovanni
    SCIENTIFIC REPORTS, 2016, 6
  • [3] Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells
    Carmen Lammi
    Chiara Zanoni
    Gilda Aiello
    Anna Arnoldi
    Giovanni Grazioso
    Scientific Reports, 6
  • [4] Berberine decreases PCSK9 expression in HepG2 cells
    Cameron, Jamie
    Ranheim, Trine
    Kulseth, Mari Ann
    Leren, Trond P.
    Berge, Knut Erik
    ATHEROSCLEROSIS, 2008, 201 (02) : 266 - 273
  • [5] Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells
    Chen, Hung-Chen
    Chen, Pei-Yi
    Wu, Ming-Jiuan
    Tai, Mi-Hsueh
    Yen, Jui-Hung
    PLOS ONE, 2016, 11 (09):
  • [6] Butein Synergizes with Statin to Upregulate Low-Density Lipoprotein Receptor ThroughHNF1α-Mediated PCSK9 Inhibition in HepG2 Cells
    Hwang, Jin-Taek
    Kim, Hyo Jin
    Choi, Hyo-Kyoung
    Park, Jae-Ho
    Chung, Sangwon
    Chung, Min-Yu
    JOURNAL OF MEDICINAL FOOD, 2020, 23 (10) : 1102 - 1108
  • [7] Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells
    Macchi, Chiara
    Greco, Maria Francesca
    Ferri, Nicola
    Magni, Paolo
    Arnoldi, Anna
    Corsini, Alberto
    Sirtori, Cesare R.
    Ruscica, Massimiliano
    Lammi, Carmen
    NUTRIENTS, 2022, 14 (01)
  • [8] Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
    Qian, Yue-Wei
    Schmidt, Robert J.
    Zhang, Youyan
    Chu, Shaoyou
    Lin, Aimin
    Wang, He
    Wang, Xiliang
    Beyer, Thomas P.
    Bensch, William R.
    Li, Weiming
    Ehsani, Mariam E.
    Lu, Deshun
    Konrad, Robert J.
    Eacho, Patrick I.
    Moller, David E.
    Karathanasis, Sotirios K.
    Cao, Guoqing
    JOURNAL OF LIPID RESEARCH, 2007, 48 (07) : 1488 - 1498
  • [9] Dihydromyricetin promotes LDL metabolism in HepG2 cells through the PCSK9/LDLR pathway
    Wang, Li-Tian
    Hu, Dan-Dan
    Liu, Hua-Rong
    Yin, Huai-Liu
    Mu, Rui
    Yang, Yu-Hang
    Zhao, Run-Yu
    Sheng, Jun
    Huang, Ye-Wei
    Wang, Xuan-Jun
    CYTA-JOURNAL OF FOOD, 2023, 21 (01) : 554 - 560
  • [10] PCSK9 gene mutations and low-density lipoprotein cholesterol
    Wu, Na-Qiong
    Li, Jian-Jun
    CLINICA CHIMICA ACTA, 2014, 431 : 148 - 153